|
Title
|
|
|
|
Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer
| |
|
Author
|
|
|
|
| |
|
Institution/Organisation
|
|
|
|
CORE-ARV-CTC ProBIO Inves
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
JAMA ONCOLOGY
| |
|
Publication
|
|
|
|
Chicago
:
Amer medical assoc
,
2019
| |
|
DOI
|
|
|
|
10.1001/JAMAONCOL.2019.0869
| |
|
Volume/pages
|
|
|
|
5
:7
(2019)
, p. 1059-1061
| |
|
ISI
|
|
|
|
000481511600025
| |
|
Pubmed ID
|
|
|
|
31046065
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|